Andrew N Bubak1, Christina N Como1, Christina M Coughlan1,2,3, Noah R Johnson1,2,3, James E Hassell1, Teresa Mescher1, Christy S Niemeyer1, Ravi Mahalingam1, Randall J Cohrs1,4, Timothy D Boyd1,2,3, Huntington Potter1,2,3, Holger A Russ5, Maria A Nagel1,6. 1. Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA. 2. Rocky Mountain Alzheimer's Disease Center, University of Colorado School of Medicine, Aurora, Colorado, USA. 3. Linda Crnic Institute for Down Syndrome Research, University of Colorado School of Medicine, Aurora, Colorado, USA. 4. Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA. 5. Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA. 6. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Abstract
BACKGROUND: Herpes zoster is linked to amyloid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, in epidemiological studies. Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyloid. METHODS: Production of intracellular amyloidogenic proteins (amylin, amyloid precursor protein [APP], and amyloid-β [Aβ]) and amyloid, as well as extracellular amylin, Aβ, and amyloid, was compared between mock- and VZV-infected quiescent primary human spinal astrocytes (qHA-sps). The ability of supernatant from infected cells to induce amylin or Aβ42 aggregation was quantitated. Finally, the amyloidogenic activity of viral peptides was examined. RESULTS: VZV-infected qHA-sps, but not mock-infected qHA-sps, contained intracellular amylin, APP, and/or Aβ, and amyloid. No differences in extracellular amylin, Aβ40, or Aβ42 were detected, yet only supernatant from VZV-infected cells induced amylin aggregation and, to a lesser extent, Aβ42 aggregation into amyloid fibrils. VZV glycoprotein B (gB) peptides assembled into fibrils and catalyzed amylin and Aβ42 aggregation. CONCLUSIONS: VZV-infected qHA-sps produced intracellular amyloid and their extracellular environment promoted aggregation of cellular peptides into amyloid fibrils that may be due, in part, to VZV gB peptides. These findings suggest that together with host and other environmental factors, VZV infection may increase the toxic amyloid burden and contribute to amyloid-associated disease progression.
BACKGROUND: Herpes zoster is linked to amyloid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, in epidemiological studies. Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyloid. METHODS: Production of intracellular amyloidogenic proteins (amylin, amyloid precursor protein [APP], and amyloid-β [Aβ]) and amyloid, as well as extracellular amylin, Aβ, and amyloid, was compared between mock- and VZV-infected quiescent primary human spinal astrocytes (qHA-sps). The ability of supernatant from infected cells to induce amylin or Aβ42 aggregation was quantitated. Finally, the amyloidogenic activity of viral peptides was examined. RESULTS:VZV-infected qHA-sps, but not mock-infectedqHA-sps, contained intracellular amylin, APP, and/or Aβ, and amyloid. No differences in extracellular amylin, Aβ40, or Aβ42 were detected, yet only supernatant from VZV-infected cells induced amylin aggregation and, to a lesser extent, Aβ42 aggregation into amyloid fibrils. VZV glycoprotein B (gB) peptides assembled into fibrils and catalyzed amylin and Aβ42 aggregation. CONCLUSIONS:VZV-infected qHA-sps produced intracellular amyloid and their extracellular environment promoted aggregation of cellular peptides into amyloid fibrils that may be due, in part, to VZVgB peptides. These findings suggest that together with host and other environmental factors, VZVinfection may increase the toxic amyloid burden and contribute to amyloid-associated disease progression.
Authors: Marie E Oskarsson; Johan F Paulsson; Sebastian W Schultz; Martin Ingelsson; Per Westermark; Gunilla T Westermark Journal: Am J Pathol Date: 2015-02-17 Impact factor: 4.307
Authors: Andrew N Bubak; Cheryl Beseler; Christina N Como; Stephen K Tyring; Christopher Haley; Teresa Mescher; James E Hassell; Randall J Cohrs; Huntington Potter; Maria A Nagel Journal: J Neurovirol Date: 2020-05-08 Impact factor: 2.643
Authors: Sigrun Alba Johannesdottir Schmidt; Katalin Veres; Henrik Toft Sørensen; Niels Obel; Victor W Henderson Journal: Neurology Date: 2022-06-08 Impact factor: 11.800
Authors: Andrew N Bubak; Cheryl Beseler; Christina N Como; Christina M Coughlan; Noah R Johnson; James E Hassell; Anna M Burnet; Teresa Mescher; D Scott Schmid; Colin Coleman; Ravi Mahalingam; Randall J Cohrs; Timothy D Boyd; Huntington Potter; Ali H Shilleh; Holger A Russ; Maria A Nagel Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226
Authors: Richard J Johnson; Fernando Gomez-Pinilla; Maria Nagel; Takahiko Nakagawa; Bernardo Rodriguez-Iturbe; Laura G Sanchez-Lozada; Dean R Tolan; Miguel A Lanaspa Journal: Front Aging Neurosci Date: 2020-09-11 Impact factor: 5.750
Authors: Karin Lopatko Lindman; Eva-Stina Hemmingsson; Bodil Weidung; Jon Brännström; Maria Josefsson; Jan Olsson; Fredrik Elgh; Peter Nordström; Hugo Lövheim Journal: Alzheimers Dement (N Y) Date: 2021-02-14